BALTIMORE--(BUSINESS WIRE)--Nov. 4, 2005--Osiris Therapeutics, Inc. announced today that its multi-center, human clinical stem cell trial for the treatment of patients suffering from heart attacks has successfully passed the first safety milestone of the trial. Additionally, the novel stem cell therapy was cleared by the presiding independent safety board to begin enrolling patients at higher doses of drug. Osiris is developing Provacel(TM) as part of a comprehensive strategic alliance with Boston Scientific Corporation (NYSE:BSX) for development and commercialization of Osiris’ mesenchymal stem cell technology in the cardiac field.
